Hiten D Patel1, Gregory A Joice2, Zeyad R Schwen2, Alice Semerjian2, Ridwan Alam2, Arnav Srivastava2, Mohamad E Allaf2, Phillip M Pierorazio2. 1. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 600 N. Wolfe Street/Marburg 134, Baltimore, MD, 21287, USA. hitenpatel@jhmi.edu. 2. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 600 N. Wolfe Street/Marburg 134, Baltimore, MD, 21287, USA.
Abstract
PURPOSE: While retroperitoneal lymph node dissection (RPLND) is traditionally reserved for nonseminomatous germ cell tumors, recent efforts to reduce long-term toxicities of radiation and chemotherapy have turned attention to its application for testicular seminomas. Currently, RPLND is reserved for the post-chemotherapy for stage II testicular seminomas; we aimed to describe current utilization of RPNLD for testicular seminomas by stage and implications for survival. METHODS: A national sample of men diagnosed with stage IA/IB/IS/IIA/IIB/IIC testicular seminoma (1988-2013) was evaluated from SEER Program registries. Stage-specific utilization of RPLND was determined. Cox proportional hazards models, adjusted for age, race, and radiotherapy, evaluated overall (OS) and cancer-specific survival (CSS) for the RPLND cohort. Adjusted models assessed predictors of RPLND. RESULTS: A total of 17,681 men (mean age 38.1 years) with testicular seminoma were included with low utilization of RPLND for stage I disease (1.3% overall) and higher rates for stage II disease (10.6% overall). There were no appreciable trends over time. Patients receiving RPLND did not appear to have worse OS or CSS on adjusted stage-by-stage analysis. Higher stage disease (IIA-IIC) was associated with greater need for RPLND while radiotherapy was associated with decreased use [OR 0.40 (0.32-0.51), p < 0.001]. CONCLUSIONS: Utilization of RPLND for testicular seminomas in the post-chemotherapy setting has remained stable over a 25-year period. Patients undergoing RPLND are a higher risk cohort but stage-by-stage survival outcomes appeared comparable to men not undergoing RPLND. Upcoming trials implementing RPLND as a first-line modality for testicular seminoma or isolated retroperitoneal relapse will help better quantify relative recurrence and survival.
PURPOSE: While retroperitoneal lymph node dissection (RPLND) is traditionally reserved for nonseminomatous germ cell tumors, recent efforts to reduce long-term toxicities of radiation and chemotherapy have turned attention to its application for testicular seminomas. Currently, RPLND is reserved for the post-chemotherapy for stage II testicular seminomas; we aimed to describe current utilization of RPNLD for testicular seminomas by stage and implications for survival. METHODS: A national sample of men diagnosed with stage IA/IB/IS/IIA/IIB/IIC testicular seminoma (1988-2013) was evaluated from SEER Program registries. Stage-specific utilization of RPLND was determined. Cox proportional hazards models, adjusted for age, race, and radiotherapy, evaluated overall (OS) and cancer-specific survival (CSS) for the RPLND cohort. Adjusted models assessed predictors of RPLND. RESULTS: A total of 17,681 men (mean age 38.1 years) with testicular seminoma were included with low utilization of RPLND for stage I disease (1.3% overall) and higher rates for stage II disease (10.6% overall). There were no appreciable trends over time. Patients receiving RPLND did not appear to have worse OS or CSS on adjusted stage-by-stage analysis. Higher stage disease (IIA-IIC) was associated with greater need for RPLND while radiotherapy was associated with decreased use [OR 0.40 (0.32-0.51), p < 0.001]. CONCLUSIONS: Utilization of RPLND for testicular seminomas in the post-chemotherapy setting has remained stable over a 25-year period. Patients undergoing RPLND are a higher risk cohort but stage-by-stage survival outcomes appeared comparable to men not undergoing RPLND. Upcoming trials implementing RPLND as a first-line modality for testicular seminoma or isolated retroperitoneal relapse will help better quantify relative recurrence and survival.
Authors: Craig R Nichols; Bruce Roth; Peter Albers; Lawrence H Einhorn; Richard Foster; Siamak Daneshmand; Michael Jewett; Padraig Warde; Christopher J Sweeney; Clair Beard; Tom Powles; Scott Tyldesley; Alan So; Christopher Porter; Semra Olgac; Karim Fizazi; Brandon Hayes-Lattin; Peter Grimison; Guy Toner; Richard Cathomas; Carsten Bokemeyer; Christian Kollmannsberger Journal: J Clin Oncol Date: 2013-09-03 Impact factor: 44.544
Authors: Andrew S Flum; Laurie Bachrach; Borko D Jovanovic; Irene B Helenowski; Sarah C Flury; Joshua J Meeks Journal: Urology Date: 2014-10-11 Impact factor: 2.649
Authors: Christian Kollmannsberger; Torgrim Tandstad; Philippe L Bedard; Gabriella Cohn-Cedermark; Peter W Chung; Michael A Jewett; Tom Powles; Padraig R Warde; Siamak Daneshmand; Andrew Protheroe; Scott Tyldesley; Peter C Black; Kim Chi; Alan I So; Malcom J Moore; Craig R Nichols Journal: J Clin Oncol Date: 2014-08-18 Impact factor: 44.544
Authors: Robert J Motzer; Eric Jonasch; Neeraj Agarwal; Clair Beard; Sam Bhayani; Graeme B Bolger; Sam S Chang; Toni K Choueiri; Brian A Costello; Ithaar H Derweesh; Shilpa Gupta; Steven L Hancock; Jenny J Kim; Timothy M Kuzel; Elaine T Lam; Clayton Lau; Ellis G Levine; Daniel W Lin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Elizabeth R Plimack; Edward N Rampersaud; Bruce G Redman; Charles J Ryan; Joel Sheinfeld; Brian Shuch; Kanishka Sircar; Brad Somer; Richard B Wilder; Mary Dwyer; Rashmi Kumar Journal: J Natl Compr Canc Netw Date: 2015-06 Impact factor: 11.908
Authors: Kevin R Rice; Stephen D W Beck; Richard Bihrle; K Clint Cary; Lawrence H Einhorn; Richard S Foster Journal: J Urol Date: 2014-05-09 Impact factor: 7.450
Authors: Paul Johnston; Stephen D W Beck; Liang Cheng; Timothy A Masterson; Richard Bihrle; Kenneth Kesler; Richard S Foster Journal: J Urol Date: 2013-03-19 Impact factor: 7.450
Authors: J Beyer; P Albers; R Altena; J Aparicio; C Bokemeyer; J Busch; R Cathomas; E Cavallin-Stahl; N W Clarke; J Claßen; G Cohn-Cedermark; A A Dahl; G Daugaard; U De Giorgi; M De Santis; M De Wit; R De Wit; K P Dieckmann; M Fenner; K Fizazi; A Flechon; S D Fossa; J R Germá Lluch; J A Gietema; S Gillessen; A Giwercman; J T Hartmann; A Heidenreich; M Hentrich; F Honecker; A Horwich; R A Huddart; S Kliesch; C Kollmannsberger; S Krege; M P Laguna; L H J Looijenga; A Lorch; J P Lotz; F Mayer; A Necchi; N Nicolai; J Nuver; K Oechsle; J Oldenburg; J W Oosterhuis; T Powles; E Rajpert-De Meyts; O Rick; G Rosti; R Salvioni; M Schrader; S Schweyer; F Sedlmayer; A Sohaib; R Souchon; T Tandstad; C Winter; C Wittekind Journal: Ann Oncol Date: 2012-11-14 Impact factor: 32.976
Authors: Hiten D Patel; Nirmish Singla; Rashed A Ghandour; Yuval Freifeld; Joseph G Cheaib; Solomon L Woldu; Phillip M Pierorazio; Aditya Bagrodia Journal: Cancer Date: 2019-07-29 Impact factor: 6.860